Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.

ABSTRACT:

Background

Bruton's tyrosine kinase (BTK) is important in B-cell signalling. Efficacy has been reported for BTK inhibitors (BTKi) in human autoimmune diseases. Canine pemphigus foliaceus (cPF) is one of the most common canine autoimmune skin diseases.

Objectives

To determine the safety and efficacy of the BTKi PRN1008 in the treatment of cPF.

Animals

Four privately owned dogs.

Methods and materials

Four dogs diagnosed with PF were administered BTKi PRN1008. Initial dosages approximated to 15 mg/kg once daily, increased to twice daily if inadequate response was seen. Treatment continued for 20 weeks, attempting to decrease to every other day. Dogs were monitored with complete blood counts, serum biochemistry panels and urinalyses, and evaluated with a modified v

SUBMITTER: Goodale EC 

PROVIDER: S-EPMC11298810 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature